In summary, these studies suggest that genetic or pharmacological inhibition of these pro-inflammatory mediators (iNOS, IL-6, CCL2, and CCL9) provides neuroprotection against stroke, which can affect pro-inflammatory mediators by modulating LCN-2. The gene discussed is LCN2; the disease is Stroke.